1,034 results on '"Giobbie‐Hurder, Anita"'
Search Results
52. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
53. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer
54. Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade
55. Supplementary Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
56. Supplementary Figure 3 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
57. Supplementary Figure 2 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
58. Supplementary Figure 5 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
59. Supplementary Figure legends from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
60. Supplementary Figure 4 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
61. 218 Prospective spatial immune cell profiling identifies features of the tumor-immune microenvironment associated with genomic alterations and patient survival in a 2,023 patient pan-cancer cohort
62. Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
63. Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience
64. Supplementary Figure 1 from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
65. EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade
66. Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma
67. Multisite Randomized Controlled Trials in Health Services Research: Scientific Challenges and Operational Issues
68. Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocytemacrophage colony stimulating factor in patients with stage III and IV melanoma.
69. Exploring anxiety as an influencing factor of the impact of exercise and mind-body prehabilitation on cognitive functioning among women undergoing breast cancer surgery.
70. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
71. Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors.
72. Measuring Costs in Multisite Randomized Controlled Trials: Lessons from the VA Cooperative Studies Program
73. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
74. Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy
75. Data from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
76. Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
77. Supplementary Figure 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
78. Data from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
79. Supplementary Figure 3 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
80. Supplementary Figure 4 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
81. Supplementary Table 1 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
82. Supplementary Figure 6 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
83. Supplementary Figure 7 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
84. Supplementary Figure Legends from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
85. Supplementary Figure 5 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
86. Supplementary Figure 2 from Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
87. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy
88. Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
89. BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells
90. Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
91. Conducting a three-country clinical trial during the COVID-19 pandemic: experience and future considerations
92. Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors
93. Abstract 3249: Circulating cytokine associations with clinical outcomes in melanoma patients treated with checkpoint inhibitors
94. Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
95. Data from The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders
96. Supplementary Data from The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders
97. Abstract 965: Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma
98. Abstract 5864: An angiogenic target of immune exclusion with checkpoint blockade in melanoma
99. Data from An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer
100. Data from A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.